VBI Vaccines Beheer

Beheer criteriumcontroles 3/4

De CEO VBI Vaccines is Jeff Baxter, benoemd in May2016, heeft een ambtstermijn van 8.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 893.55K, bestaande uit 78.1% salaris en 21.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.071% van de aandelen van het bedrijf, ter waarde $ 10.14. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.2 jaar en 6.8 jaar.

Belangrijke informatie

Jeff Baxter

Algemeen directeur

US$893.5k

Totale compensatie

Percentage CEO-salaris	78.1%
Dienstverband CEO	8.5yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	7.2yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

Analyse CEO-vergoeding

Hoe is Jeff Baxter's beloning veranderd ten opzichte van VBI Vaccines's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$894k	US$698k	-US$94m
Sep 30 2023	n/a	n/a	-US$115m
Jun 30 2023	n/a	n/a	-US$119m
Mar 31 2023	n/a	n/a	-US$120m
Dec 31 2022	US$2m	US$678k	-US$113m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$605k	-US$70m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$2m	US$535k	-US$46m
Sep 30 2020	n/a	n/a	-US$42m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$1m	US$500k	-US$55m
Sep 30 2019	n/a	n/a	-US$63m
Jun 30 2019	n/a	n/a	-US$62m
Mar 31 2019	n/a	n/a	-US$66m
Dec 31 2018	US$1m	US$465k	-US$64m
Sep 30 2018	n/a	n/a	-US$56m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$43m
Dec 31 2017	US$826k	US$450k	-US$39m

Compensatie versus markt: De totale vergoeding ($USD 893.55K ) Jeff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.02K ).

Compensatie versus inkomsten: De vergoeding van Jeff is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jeff Baxter (63 yo)

8.5yrs

Tenure

US$893,547

Compensatie

Mr. Jeffery R. Baxter, also known as Jeff, FCMA, has been the Chief Executive Officer and President of VBI Vaccines Inc. since May 2016. Mr. Baxter has been the Chief Executive Officer and President of VBI...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffery Baxter	President	8.5yrs	US$893.55k	0.071% $ 10.1
Nell Beattie	CFO, Head of Corporate Development & Director	1.6yrs	geen gegevens	0.0079% $ 1.1
David Anderson	Chief Scientific Officer	8.5yrs	US$564.56k	0.017% $ 2.5
Francisco Diaz-Mitoma	Chief Medical Officer	8.8yrs	US$549.22k	0.049% $ 7.0
Nicole Anderson	Director of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Athena Kartsaklis	Senior VP of Finance	7.2yrs	geen gegevens	geen gegevens
Avi Mazaltov	Global Head of Manufacturing & GM of SciVac	7.5yrs	geen gegevens	0.025% $ 3.5
Misha Nossov	Senior VP of Global Commercial Supply Strategy & Head of Europe	4.8yrs	geen gegevens	geen gegevens
T. Buckley	Senior Vice President of Business Development	4.8yrs	geen gegevens	geen gegevens
John Dillman	Chief Commercial Officer	2.3yrs	geen gegevens	geen gegevens

7.2yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VBIV.Q is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffery Baxter	President	8.5yrs	US$893.55k	0.071% $ 10.1
Nell Beattie	CFO, Head of Corporate Development & Director	1.6yrs	geen gegevens	0.0079% $ 1.1
Steven S. Gillis	Independent Chairperson of the Board	8.5yrs	US$194.03k	0.0098% $ 1.4
Denis Burger	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Peter Patriarca	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Stanley Plotkin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Damian Braga	Chairperson of the Commercial Advisory Board & Independent Director	4.7yrs	US$105.18k	0% $ 0
Michel De Wilde	Independent Director and Chair of Scientific & Clinical Advisory Board	8.5yrs	US$107.68k	0.0058% $ 0.8
Blaine McKee	Independent Director	5.8yrs	US$120.18k	0% $ 0
Joanne Cordeiro	Independent Director	5.6yrs	US$127.68k	0% $ 0
Robert Pass	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Adam Finn	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VBIV.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

VBI Vaccines Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

Recent updates

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

Consensus revenue estimates fall by 49%

Consensus revenue estimates fall by 49%

No longer forecast to breakeven

Price target decreased to US$6.67

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

Consensus forecasts updated

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults